{"schema_version":"secwatch.filing_event.v1","accession":"0001396814-25-000011","form_type":"8-K","ticker":"PCRX","cik":"0001396814","company_name":"Pacira BioSciences, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.516181+00:00","generated_at":"2026-05-28T04:45:49.154534+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pacira preliminary FY2024 revenue $701M (+3.9% YoY); announces 5x30 growth plan","bullets":["FY2024 total revenue of $701.0M, up from $675.0M in 2023; Q4 EXPAREL $147.7M.","EXPAREL net sales $549.0M, ZILRETTA $118.1M, iovera° $22.8M for full year.","Unveils 5x30 plan: treat >3M patients/year, double-digit revenue CAGR, 5pp gross margin improvement by 2030.","Inducement grants: options for 20,300 shares and RSUs for 30,400 shares at $18.40.","Revenue preliminary and unaudited; full Q4 and FY results with guidance expected Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001396814-25-000011","json":"https://secwatch.observer/filing/0001396814-25-000011.json","markdown":"https://secwatch.observer/filing/0001396814-25-000011.md","text":"https://secwatch.observer/filing/0001396814-25-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000011/0001396814-25-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1396814/000139681425000011/pcrx-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:45:49.154534+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}